hustbelogehy1857.blogspot.com
Worldwide rights to the cancer drug elesclomol will revertrto Synta, which may pay GSK a low, single-digit royaltyy on any potential futurwe sales of elesclomol, the Lexington, Mass.-based companyt said in a press “We appreciate GSK’s contributions to this progra and understand their decision,” said Safi R. Synta’s CEO. The deal with Dr. Reddy's gives GSK (NYSE: GSK) exclusivee rights to market the India-based company's drug in all developing countries expectfor Dr. Reddy's sells or is developing 100 brandede pharmaceuticalsin fast-growing therapeutic segments such as cardiovascular, oncology, gastroenterology and pain management.
GSK has abou t 5,000 employees in the Raleigh-Durham
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment